NYSE:WM
NYSE:WMCommercial Services

Waste Management (WM) Valuation Check After Recent Share Price Pullback

Waste Management (WM) has quietly outperformed many defensive names this year, and with the stock recently pulling back from its highs, investors are asking whether this is a healthy pause or an early warning sign. See our latest analysis for Waste Management. At around $209.31 per share, WM has given investors a modest 4.37 percent year to date share price return. A 93.91 percent total shareholder return over five years suggests the recent pullback looks more like cooling momentum than a...
NasdaqGS:PGNY
NasdaqGS:PGNYHealthcare

Progyny (PGNY): Revisiting Valuation After a 10% Monthly Rally and 57% One-Year Share Price Surge

Progyny (PGNY) has quietly climbed about 10% over the past month and roughly 57% over the past year, prompting a closer look at what is driving sentiment around this fertility benefits specialist. See our latest analysis for Progyny. That recent 10.4% 1 month share price return, on top of a strong year to date share price gain, suggests momentum is rebuilding as investors refocus on Progyny’s growth and reassess past worries reflected in its weaker multi year total shareholder returns. If...
NasdaqGS:BIIB
NasdaqGS:BIIBBiotechs

Is Biogen’s Recent 20% Rally Just the Start as Valuation Signals Turn Attractive?

Wondering if Biogen is quietly becoming a bargain again, or if the market still has it priced like yesterday's story? This breakdown will walk you through what the numbers are really saying about its value. After a tough few years, the stock has started to show signs of life, with shares up around 1.5% over the last week, 16.0% over the past month, and 20.3% year to date, even though the 3-year and 5-year returns remain negative. Recent moves have been driven by shifting sentiment around...
XTRA:HLAG
XTRA:HLAGShipping

Is Hapag-Lloyd (XTRA:HLAG) Quietly Mispriced? A Fresh Look at Its Valuation After Recent Share Price Stabilisation

Hapag-Lloyd (XTRA:HLAG) has been quietly grinding higher, with the stock up around 1% today and roughly 4% over the past week, even as year to date performance remains negative. See our latest analysis for Hapag-Lloyd. That recent pop in the share price looks more like the start of stabilising momentum than a full trend change. A modest 3 month share price return contrasts sharply with the weak year to date share price return and still solid 5 year total shareholder return. If Hapag-Lloyd has...
NYSE:PRMB
NYSE:PRMBBeverage

Weighing Primo Brands Valuation After 9.1% Rebound and Strategic Refocus in 2025

If you are wondering whether Primo Brands at around $15.77 is a bargain or a value trap, you are not alone. This stock has all the ingredients of a classic valuation puzzle. Over the last month the share price has climbed roughly 9.1%, even though it is still down 49.1% year to date and 47.7% over the last year. This suggests that sentiment is shifting, but the long-term scars are still visible. That recent rebound has come as investors digested a series of strategic updates, including...
NasdaqGS:COST
NasdaqGS:COSTConsumer Retailing

Does Costco Still Justify Its Premium Price After Recent Share Price Slip?

If you have ever wondered whether Costco Wholesale is still a smart buy at around $887 a share, you are not alone. Plenty of investors are trying to figure out if the current price still leaves room for value. The stock has slipped recently, down about 2.7% over the last week, 3.8% over the past month, and 2.5% year to date, yet it still sits on gains of 89.6% over 3 years and 150.5% over 5 years, which keeps the long term story in focus. Much of the recent share price action has been driven...
NYSE:CCK
NYSE:CCKPackaging

Has the Recent Pullback Created a Fresh Opportunity in Crown Holdings Stock?

Wondering if Crown Holdings is actually good value at around $94 a share, or if the easy money has already been made, you are not alone. Despite being up 16.0% year to date and 8.5% over the last year, the stock has cooled recently with a 4.0% dip over the past week and a 3.7% slide across the last month. Those moves have come as investors reassess packaging stocks more broadly, with Crown often in the conversation thanks to its global footprint and exposure to consumer staples. At the same...
NasdaqGS:AMD
NasdaqGS:AMDSemiconductor

Assessing AMD (AMD) Valuation After Renewed China AI Chip Sales Approval

Advanced Micro Devices (AMD) stock is back in the spotlight after President Donald Trump moved to let US chipmakers resume selling advanced AI processors to approved customers in China, subject to new oversight and a 25% fee. See our latest analysis for Advanced Micro Devices. The policy shift arrives while AMD is already riding a powerful AI wave, with a 90 day share price return of 38.91% and a 1 year total shareholder return of 73.49%, signaling momentum that investors clearly still buy...
NasdaqCM:MARA
NasdaqCM:MARASoftware

Should MARA Holdings’ Convertible Debt And Bitcoin Positioning Require Action From MARA (MARA) Investors?

In recent days, VanEck’s Matthew Sigel highlighted that MARA Holdings’ US$3.30 billion in convertible debt and structurally high short interest mean its valuation is heavily shaped by its balance sheet rather than simple bitcoin exposure. At the same time, a very large 43,033 BTC transfer to Jack Mallers’ Twenty One ahead of its NYSE listing has put fresh attention on where MARA sits among the largest corporate bitcoin holders and how its financing choices influence its risk...
NasdaqGS:JD
NasdaqGS:JDMultiline Retail

Is JD.com Now a Value Opportunity After a 22.8% Share Price Slide?

If you are wondering whether JD.com is quietly turning into a value opportunity after years of pain, you are not alone. This is exactly the question we are going to unpack. Despite a tough run, with the share price down about 1.2% over the last week, 6.6% over the past month, and still roughly 22.8% lower over the last year, the stock is starting to look more interesting to value focused investors. Recent headlines have focused on JD.com sharpening its focus on core e commerce, doubling down...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Is Novo Nordisk Still Attractively Priced After Recent Share Price Swings?

Wondering if Novo Nordisk is still worth buying after all the excitement around weight loss and diabetes treatments, or if the best days are already priced in. The stock has been choppy recently, down 2.6% over the last week but still up 2.7% over the past month, and longer term it has swung from a 53.8% gain over five years to a steep 60.7% drop in the last year, which says a lot about shifting expectations and risk appetite. Those moves sit against a backdrop of ongoing buzz around its GLP...
NasdaqGS:UAL
NasdaqGS:UALAirlines

Is It Too Late To Consider United Airlines After Its Strong Multi Year Share Price Rally

Wondering if United Airlines Holdings is still good value after its big run, or if most of the upside has already been priced in? You are not alone. That is exactly what this piece will unpack. United's share price has climbed 3.3% over the last week, 7.3% over the past month, and is up 9.5% year to date, adding to a hefty 136.2% gain over three years and 123.7% over five years that has reshaped how investors see its risk and reward profile. Those moves have come as investors react to a mix...
NYSE:VMC
NYSE:VMCBasic Materials

Vulcan Materials (VMC): Reassessing Valuation After a Steady 2024 Climb and Recent Pullback

Vulcan Materials (VMC) has been quietly grinding higher this year, and its recent price action is giving investors a chance to reassess what they are really paying for its steady infrastructure exposure. See our latest analysis for Vulcan Materials. The 13.88% year to date share price return suggests momentum is still broadly constructive. However, the recent pullback toward 291.04 hints at investors periodically reassessing infrastructure demand and what they are willing to pay for Vulcan’s...
NasdaqCM:CLSK
NasdaqCM:CLSKSoftware

Should CleanSpark’s Bitcoin Windfall and AI Pivot Require Action From CleanSpark (CLSK) Investors?

CleanSpark, Inc. has already reported unaudited October 2025 production of 587 Bitcoin and fiscal 2025 results showing revenue of US$766.31 million and net income of US$364.46 million, marking a major turnaround from the prior year's loss. Alongside record profitability, the company is expanding into AI and high-performance computing while holding 13,054 Bitcoin and funding growth through US$1.15 billions in zero-coupon convertible notes and large-scale share repurchases. We’ll now examine...
NYSE:AZO
NYSE:AZOSpecialty Retail

AutoZone (AZO) Q1 2026 Margin Compression Challenges Bullish Earnings Growth Narratives

AutoZone (AZO) opened fiscal Q1 2026 with total revenue of $4.6 billion and basic EPS of $31.88, setting the stage against a backdrop where trailing twelve month revenue sits at $19.3 billion and EPS at $147.34. Over recent quarters the company has seen revenue move from $6.2 billion in Q4 2024 to $6.2 billion in Q4 2025 and then to $4.6 billion in Q1 2026, while quarterly EPS tracked from $53.0 to $50.0 and now $31.9, leaving investors weighing solid top line scale against signs of...
NasdaqGS:OMCL
NasdaqGS:OMCLMedical Equipment

Is Omnicell’s (OMCL) Titan XT Launch a Turning Point in Its SaaS Automation Strategy?

Omnicell recently launched Omnicell Titan XT in the United States, an enterprise-grade automated dispensing system powered by its cloud-based, HITRUST-certified OmniSphere platform to unify medication management across health systems. The system’s AI-enabled inventory intelligence and embedded FiveRights safety safeguards position Titan XT as a platform play aimed at reducing medication errors and optimizing pharmacy and nursing workflows across entire hospital networks. Next, we’ll examine...
XTRA:AFX
XTRA:AFXMedical Equipment

Is Carl Zeiss Meditec’s (XTRA:AFX) Oncology Imaging Push Quietly Redefining Its Long‑Term Growth Story?

In November 2025, FluoGuide A/S announced a non-exclusive collaboration agreement with ZEISS Medical Technologies to advance FG001 for tumor imaging and surgical margin assessment in head and neck cancer, focused on supporting the clinical phase and with no initial payment or expected financial impact in 2025. This partnership underlines Carl Zeiss Meditec’s continued push into precision oncology imaging, where integrating advanced optics with novel tracers could broaden its long-term...
NYSE:OWL
NYSE:OWLCapital Markets

Assessing Blue Owl Capital’s Valuation After a Volatile Year and Recent Fundraising Expansion

Wondering if Blue Owl Capital is a bargain or a value trap at around $16 a share? You are not alone, and this is exactly the kind of stock where a closer look at valuation can really pay off. The share price has bounced about 6.6% over the last week and 3.8% over the past month, but that still sits against a much tougher backdrop with the stock down 32.1% year to date and 28.3% over the last year. Even so, the 3 year and 5 year returns are 59.3% and 86.7% respectively. Some of this recent...
NYSE:FLO
NYSE:FLOFood

Flowers Foods (FLO): Reassessing Valuation After This Year’s Share Price Slide

Flowers Foods (FLO) has been sliding this year, and that weak share performance is exactly why the stock is getting fresh attention from value focused investors looking for a reset. See our latest analysis for Flowers Foods. That drop has left the share price at about $10.71, and with a roughly 48% year to date share price return decline and a similar slide in the one year total shareholder return, momentum clearly looks to be fading rather than stabilising. If Flowers Foods' slump has you...